MRK vs REGN
By Alex · Tickerpine
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | REGN |
|---|---|---|
| Price | $147.76 | $955.47 |
| Market cap | $364.26B | $98.84B |
| P/E ratio | 149.3 | 21.1 |
| ROE | 5.06% | 14.95% |
| Profit margin | 3.64% | 28.51% |
| Revenue growth | 4.70% | 36.30% |
| Dividend yield | 2.30% | 0.39% |
| Beta | 0.12 | 0.10 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs REGN in plain English
- MRK is the bigger company — about 3.7× the market cap of REGN.
- REGN is cheaper on earnings (P/E 21.1 vs 149.3).
- REGN earns a higher return on equity (15% vs 5%).
- REGN is growing revenue faster (36% vs 5%).
- MRK has the higher dividend yield (2.30% vs 0.39%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.